All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @landyjarocha on TikTok · 62s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @landyjarocha's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00The first thing I wanted to do was to make a video of Mikasso and the Moonjaro
  2. 0:04and the other one, the
  3. 0:05K-Sonas and the L'Avoemen and the L'Avoemen and the L'Avoemen and the Rasso.
  4. 0:07The specific method of the Rasso is that the way that it's like making a K-BnL
  5. 0:11is because you have the minimum laboratory.

GLP-1 injection technique: what TikTok gets right and wrong

LANDY JAROCHA

TikTok creator

90.4K viewsWatch on TikTok

Quick answer

The video caption describes a tutorial on self-injecting a weekly GLP-1 dose into the upper arm, a technique that is clinically valid for approved medications like semaglutide and tirzepatide. However, the transcript contains no identifiable clinical instructions and references multiple apparent medication names that do not correspond to any real GLP-1 drugs or pharmaceutical terminology. Given the video's reach, the absence of verifiable, accurate injection guidance represents a potential patient safety concern.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For GLP-1 injection technique: what TikTok gets right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

GLP-1 injection technique: what TikTok gets right and wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "GLP-1 injection technique: what TikTok gets right and wrong" from LANDY JAROCHA. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video caption describes a tutorial on self-injecting a weekly GLP-1 dose into the upper arm, a technique that is clinically valid for approved medications like semaglutide and tirzepatide.

The reason this review is not generic is the source wording and the canonical claim label "glp1 c mo aplicarse la dosis semanal de tratamiento glp1 en el br." In this clip, the useful excerpt is: "The first thing I wanted to do was to make a video of Mikasso and the Moonjaro and the other one, the K-Sonas and the L'Avoemen and the L'Avoemen and the L'Avoemen and the Rasso." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Johansson et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video caption describes a tutorial on self-injecting a weekly GLP-1 dose into the upper arm, a technique that is clinically valid for approved medications like semaglutide and tirzepatide.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video caption describes a tutorial on self-injecting a weekly GLP-1 dose into the upper arm, a technique that is clinically valid for approved medications like semaglutide and tirzepatide. However, the transcript contains no identifiable clinical instructions and references multiple apparent medication names that do not correspond to any real GLP-1 drugs or pharmaceutical terminology. Given the video's reach, the absence of verifiable, accurate injection guidance represents a potential patient safety concern.
  • Upper arm subcutaneous injection is an FDA-approved site for semaglutide and tirzepatide, confirmed in the prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound.
  • Johansson et al. (2021, Diabetes Technology and Therapeutics) found that injection into lipohypertrophic tissue can reduce drug absorption by up to 25%, making site rotation a clinical priority, not just a preference.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Upper arm subcutaneous injection is an FDA-approved site for semaglutide and tirzepatide, confirmed in the prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound.
  • Johansson et al. (2021, Diabetes Technology and Therapeutics) found that injection into lipohypertrophic tissue can reduce drug absorption by up to 25%, making site rotation a clinical priority, not just a preference.
  • Mounjaro and Ozempic use different pen delivery systems. Instructions for one device do not automatically apply to the other.
  • The transcript from this 90,000-view video contains no identifiable clinical terminology or injection guidance that can be evaluated for accuracy.
  • Self-injection technique for GLP-1 medications should be reviewed by a licensed healthcare provider. TikTok tutorials, even well-intentioned ones, are not a substitute for device-specific training.
  • Needle length matters for subcutaneous injection: 4mm needles are generally preferred for most patients to avoid intramuscular injection, per injection technique guidelines from the Forum for Injection Technique.
  • Compounded versions of semaglutide or tirzepatide may use different delivery formats than FDA-approved branded pens. Injection instructions are not interchangeable between compounded and brand-name products.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @landyjarocha actually say?

Honestly? It's hard to say with any confidence. The transcript from this 90,000-view video is almost entirely incoherent. The creator appears to reference several GLP-1 medications, including what sounds like Mounjaro and possibly semaglutide, but the audio quality and transcription produce strings like "the K-BnL" and "the minimum laboratory" that don't correspond to any real clinical terminology or brand names.

The video caption claims to show viewers how to self-inject a weekly GLP-1 dose in the arm. That's a legitimate topic worth covering. Self-injection technique matters for absorption and safety. But based on the available transcript, we cannot verify what specific instructions, if any, were actually given. References to "Mikasso," "K-Sonas," and "L'Avoemen" do not correspond to any known GLP-1 medications or pharmaceutical terms.

Does the science back this up?

The general premise, that GLP-1 receptor agonists like semaglutide and tirzepatide can be self-injected subcutaneously in the upper arm, is supported by clinical data. Whether the specific technique demonstrated in this video is accurate is impossible to assess from the transcript alone.

According to prescribing information for Ozempic (semaglutide) and Mounjaro (tirzepatide), subcutaneous injection into the abdomen, thigh, or upper arm is approved. Rotation of injection sites is recommended to reduce lipohypertrophy, a condition where fatty tissue builds up from repeated injections in the same spot. A 2021 review by Johansson et al. in Diabetes Technology and Therapeutics found that improper injection technique, including injecting into lipohypertrophic tissue, significantly reduced drug absorption and glycemic control. The upper arm is a valid site, but technique matters: the needle must reach subcutaneous tissue, not muscle or skin surface.

What did they get wrong (or right)?

We can't credit or correct specific technique points because the transcript doesn't yield coherent instructions. That itself is the problem. A video with 90,000 views claiming to teach injection technique for prescription medications should be clearly audible and accurately transcribed. If viewers are walking away having half-absorbed garbled advice about how to inject a drug that can cause nausea, vomiting, pancreatitis, and injection site reactions, that's a real safety concern.

What's also worth flagging: the video conflates multiple GLP-1 medications without making clear that these drugs have different formulations, delivery devices, and dosing schedules. Mounjaro uses a single-dose auto-injector pen. Ozempic uses a multi-dose dial pen. The injection mechanics are not identical. Treating them interchangeably in a tutorial is, at minimum, misleading to viewers who may be on one drug and applying instructions meant for another.

What should you actually know?

If you're self-injecting a GLP-1 medication, here's what the clinical evidence actually says. Subcutaneous injections should go into the fatty tissue just beneath the skin, not muscle. For the upper arm, this typically means the posterior or lateral aspect. Pinching the skin may help if you have less body fat in that area. Needle length matters: most GLP-1 pens use 4mm or 8mm needles, and shorter needles reduce the risk of intramuscular injection.

Rotate your injection sites. The FDA and endocrinology guidelines consistently recommend this. Inject at room temperature when possible, as cold medication can increase injection site discomfort. Never share pens, even if you change the needle. And critically, your injection technique should be reviewed by a licensed healthcare provider, not learned exclusively from a TikTok video, regardless of how many views it has.

  • Approved injection sites for semaglutide and tirzepatide: abdomen, upper thigh, upper arm
  • Rotate sites at least 1 cm from previous injection to reduce lipohypertrophy risk
  • Lipohypertrophy from poor rotation can reduce drug absorption by up to 25% (Johansson et al., 2021)
  • Different GLP-1 pens have different mechanisms. Do not apply instructions for one pen to another without confirming they match your device

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

LANDY JAROCHA · TikTok creator

90.4K views on this video

Cómo aplicarse la dosis semanal de tratamiento #GLP1 en el brazo

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about upper arm subcutaneous injection?

Upper arm subcutaneous injection is an FDA-approved site for semaglutide and tirzepatide, confirmed in the prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound.

What does the video say about johansson et al. (2021, diabetes technology?

Johansson et al. (2021, Diabetes Technology and Therapeutics) found that injection into lipohypertrophic tissue can reduce drug absorption by up to 25%, making site rotation a clinical priority, not just a preference.

What does the video say about mounjaro?

Mounjaro and Ozempic use different pen delivery systems. Instructions for one device do not automatically apply to the other.

What does the video say about the transcript from this 90,000-view video contains no identifiable clinical?

The transcript from this 90,000-view video contains no identifiable clinical terminology or injection guidance that can be evaluated for accuracy.

What does the video say about self-injection technique for glp-1 medications should be reviewed by a?

Self-injection technique for GLP-1 medications should be reviewed by a licensed healthcare provider. TikTok tutorials, even well-intentioned ones, are not a substitute for device-specific training.

What does the video say about needle length matters for subcutaneous injection: 4mm needles?

Needle length matters for subcutaneous injection: 4mm needles are generally preferred for most patients to avoid intramuscular injection, per injection technique guidelines from the Forum for Injection Technique.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by LANDY JAROCHA, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.